{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:29:39Z","timestamp":1791358179069,"version":"4.3.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2038,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Vasoconstrictor drugs may improve renal function in hepatorenal syndrome (HRS), but the effect on mortality has not been established. We therefore performed a systematic review of randomized trials on vasoconstrictor drugs for type 1 or type 2 HRS. Mortality was the primary outcome measure. Eligible trials were identified through electronic and manual searches. Intention-to-treat random effects meta-analyses were performed. Ten randomized trials on terlipressin alone or with albumin, octreotide plus albumin, and noradrenalin plus albumin were included. The total number of patients was 376. Overall, vasoconstrictor drugs used alone or with albumin reduced mortality compared with no intervention or albumin (relative risk [RR], 0.82; 95% confidence interval [CI], 0.70\u20130.96). In subgroup analyses, the effect on mortality was seen at 15 days (RR, 0.60; 95% CI, 0.37\u20130.97) but not at 30 days (RR, 0.74; 95% CI, 0.40\u20131.39), 90 days (RR, 0.89; 95% CI, 0.66\u20131.22), or 180 days (RR, 0.83; 95% CI, 0.65\u20131.05). Subgroup analyses stratified by the treatments assessed showed that terlipressin plus albumin reduced mortality compared with albumin (RR, 0.81; 95% CI, 0.68\u20130.97). The effect was seen in subgroup analyses of type 1 but not type 2 HRS. The remaining trials were small and found no beneficial or harmful effects of the treatments assessed.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Terlipressin plus albumin may prolong short-term survival in type 1 HRS. The duration of the response should be considered when making treatment decisions and in the timing of potential liver transplantations. Considering the small number of patients included, the evidence does not allow for treatment recommendations regarding type 2 HRS or any of the remaining treatment comparisons assessed. (Hepatology 2009.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.23286","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T14:15:57Z","timestamp":1252505757000},"page":"576-584","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":223,"title":["Systematic Review of Randomized Trials on Vasoconstrictor Drugs for Hepatorenal Syndrome"],"prefix":"10.1097","volume":"51","author":[{"given":"Lise L.","family":"Gluud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20241201","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.","volume":"23","author":"Arroyo","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R2-28-20241201","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"R3-28-20241201","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"R4-28-20241201","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome.","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R6-28-20241201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.","volume":"134","author":"Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"R7-28-20241201","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gut.49.5.729","article-title":"The hepatorenal syndrome.","volume":"49","author":"Dagher","year":"2001","journal-title":"Gut"},{"key":"R8-28-20241201","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1592\/phco.24.11.1050.36144","article-title":"The role of vasopressin in vasodilatory septic shock.","volume":"24","author":"Obritsch","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R9-28-20241201","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(82)91689-0","article-title":"Controlled trial of terlipressin (Glypressin) versus vasopressin in the early treatment of oesophageal varices.","volume":"2","author":"Freeman","year":"1982","journal-title":"Lancet"},{"key":"R10-28-20241201","first-page":"1054","article-title":"Hepatorenal syndrome. Longterm treatment with terlipressin as a bridge to liver transplantation.","volume":"41","author":"GanneCarrie","year":"1996","journal-title":"Dig Dis Sci"},{"key":"R11-28-20241201","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gut.26.12.1385","article-title":"Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis.","volume":"26","author":"Lenz","year":"1985","journal-title":"Gut"},{"key":"R12-28-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.","volume":"27","author":"Guevara","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R13-28-20241201","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0168-8278(99)80025-7","article-title":"Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients.","volume":"30","author":"Kaffy","year":"1999","journal-title":"J Hepatol"},{"key":"R14-28-20241201","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.","volume":"36","author":"Duvoux","year":"2002","journal-title":"HEPATOLOGY"},{"issue":"4","key":"R15-28-20241201","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome.","author":"Gluud","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-28-20241201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial.","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R17-28-20241201","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"MartinLlahi","year":"2008","journal-title":"Gastroenterology"},{"key":"R18-28-20241201","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R19-28-20241201","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, doubleblind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R20-28-20241201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/039139880903200303","article-title":"Terlipressin for hepatorenal syndrome: a metaanalysis of randomized trials.","volume":"32","author":"Fabrizi","year":"2009","journal-title":"Int J Artif Organs"},{"key":"R21-28-20241201","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research.","volume":"163","author":"Gluud","year":"2006","journal-title":"Am J Epidemiol"},{"key":"R22-28-20241201","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: metaepidemiological study.","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"R23-28-20241201","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/ije\/dym020","article-title":"Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.","volume":"36","author":"Hrobjartsson","year":"2007","journal-title":"Int J Epidemiol"},{"key":"R24-28-20241201","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-9-2","article-title":"Assessment of regressionbased methods to adjust for publication bias through a comprehensive simulation study.","volume":"9","author":"Moreno","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"R25-28-20241201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"R26-28-20241201","first-page":"123","article-title":"Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome.","volume":"7","author":"Yang","year":"2001","journal-title":"J Internal Int Medicine"},{"key":"R27-28-20241201","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, doubleblind, placebocontrolled, crossover study.","volume":"38","author":"PomierLayrargues","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R28-28-20241201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"issue":"Suppl","key":"R29-28-20241201","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study. Abstract.","volume":"48","author":"Angeli","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R30-28-20241201","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R31-28-20241201","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from metaanalyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"Int J Epidemiol"},{"key":"R32-28-20241201","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.295.10.1147","article-title":"Quality of reporting of noninferiority and equivalence randomized trials.","volume":"295","author":"Le Henanff","year":"2006","journal-title":"JAMA"},{"key":"R33-28-20241201","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"R34-28-20241201","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.","volume":"291","author":"Chan","year":"2004","journal-title":"JAMA"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23286","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201002000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:29:16Z","timestamp":1733059756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201002000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23286","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}